secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001213900-25-120676
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka Therapeutics appoints Christopher Martin to board; Cameron Turtle resigns
-------------------------------------------------------------------------------

- Cameron Turtle resigned as director on Dec 11, 2025; not due to disagreement with the company.
- Christopher Martin appointed as Class II director, Chair of Compensation Committee, and Audit Committee member.
- Martin previously Chief Commercial Officer at Verona Pharma, acquired by Merck for ~$10B in Oct 2025.
- He received an option to buy 35,000 shares vesting over 3 years; annual cash retainers: $40K (board), $12K (Comp Chair), $7.5K (Audit).
- Martin also serves on the board of Edgewise Therapeutics (EWTX).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390025120676/0001213900-25-120676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390025120676/ea0268925-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-120676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer